{
  "id": 10404098,
  "title": "Medytox Gains NMPA Approval for NEURAMIS Filler",
  "url": "https://urgent.news/2026/09/28/medytox-gains-nmpa-approval-for-neuramis-filler",
  "topic": "business",
  "section": "Business",
  "published": "2026-09-28T08:54:53.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=277760"
  },
  "original_language": "en",
  "account": "On September 28, Medytox announced it had received product approval from China's National Medical Products Administration (NMPA) for the hyaluronic acid filler \"NEURAMIS Volume Lidocaine.\" This approval follows the earlier approval of \"NEURAMIS Deep Lidocaine,\" bringing Medytox's lineup of hyaluronic acid fillers to a total of two. Medytox plans to sell \"NEURAMIS\" in China under the brand name \"Fillux.\"\n\nDeveloped using Medytox's proprietary technology, NEURAMIS is a hyaluronic acid filler with a residual level of the cross-linking agent BDDE reduced below the standard threshold. This reduction aims to minimize the risk of side effects. The NEURAMIS Volume Lidocaine variant includes lidocaine, a local anesthetic, which helps reduce patients' pain during the procedure. Specifically, NEURAMIS Volume Lidocaine is designed to address facial wrinkles and mid-face volume.\n\nMedytox cited the rapidly growing aesthetic medicine market in China, driven by younger consumers, as a key factor in its expansion. The company also mentioned that while they continue to expand their locally tailored product portfolio, they will engage in follow-up procedures in close collaboration with their partner company. Their goal is to launch products in China by the fourth quarter of the year.",
  "summary": "Medytox said on Sept. 28, that it has obtained product approval from China’s National Medical Products Administration (NMPA) for the hyaluronic acid filler “NEURAMIS Volume Lidocaine.”In addition to “NEURAMIS Deep Lidocaine,” which had previously received product approval in China, Medytox has now a",
  "key_points": [
    "Medytox received NMPA approval for NEURAMIS Volume Lidocaine on September 28",
    "NEURAMIS is a hyaluronic acid filler with reduced BDDE for lower side effects risk",
    "Company targets China's growing aesthetic market for NEURAMIS launch by Q4"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}